|
Glioblastoma
|
0.400 |
Biomarker
|
disease |
LHGDN |
Glioblastoma patients showed elevated levels of membrane particle-associated prominin-1/CD133, which decreased dramatically in the final stage of the disease.
|
18096722 |
2008 |
|
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Glioblastomas (GBM) may contain a variable proportion of active cancer stem cells (CSCs) capable of self-renewal, of aggregating into CD133(+) neurospheres, and to develop intracranial tumors that phenocopy the original ones.
|
22174890 |
2011 |
|
Glioblastoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
GBM CSCs were detected with CD133/1 and CD111 antibodies after co-culture studies.
|
23737374 |
2013 |
|
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
CD133-expressing tumour cells isolated from both human glioma xenografts and primary patient glioblastoma specimens preferentially activate the DNA damage checkpoint in response to radiation, and repair radiation-induced DNA damage more effectively than CD133-negative tumour cells.
|
17051156 |
2006 |
|
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
CD133 mRNA and CD133 protein could be detected in all relevant types of glioblastoma cell lines.
|
21901757 |
2011 |
|
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
CD133 as a marker for regulation and potential for targeted therapies in glioblastoma multiforme.
|
22748652 |
2012 |
|
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
CD133(+) GSCs, a kind of GSCs line, was established from human glioblastoma tissues.
|
26150336 |
2015 |
|
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
CD133, a putative stem cell marker in normal tissue and malignant brain tumors, enhances multidrug resistant gene 1 (MDR1) expression following chemotherapy in adult malignant glioblastomas.
|
28137267 |
2017 |
|
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
CD133 Regulates IL-1β Signaling and Neutrophil Recruitment in Glioblastoma.
|
28736425 |
2017 |
|
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
CD133+ GSCs express significantly higher ASAH1 compared to CD133- GSCs and serum-cultured glioblastoma cell lines, such as U87MG.
|
29348854 |
2017 |
|
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
CD133 Expression in Glioblastoma Multiforme: A Literature Review.
|
30555755 |
2018 |
|
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
CD133 has reproducibly been shown to correlate with disease progression, recurrence, and poor overall survivorship in the malignant adult brain tumor, glioblastoma (GBM).
|
31695152 |
2020 |
|
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
A CD133(+) U87 glioma cell population was isolated from parental U87 glioblastoma cells using magnetic cell sorting technology.
|
19326372 |
2009 |
|
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
A CD133-related gene expression signature identifies an aggressive glioblastoma subtype with excessive mutations.
|
21220328 |
2011 |
|
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
A stem cell marker, CD133, was reported to predict recurrence patterns in intracranial glioblastoma.
|
29180077 |
2018 |
|
Glioblastoma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
Aberrant methylation of CD133 was observed in glioblastoma.
|
26757925 |
2016 |
|
Glioblastoma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
Abnormal DNA methylation of CD133 in colorectal and glioblastoma tumors.
|
18829568 |
2008 |
|
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Additionally, HMGA2 expression was increased in CD133+ GBM neurosphere cells compared to CD133- cells.
|
27102002 |
2016 |
|
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Association of glial to mesenchymal transition (GMT)-related molecular with ObR expression and VM formation in glioblastoma tissues indicated that ObR-positive glioblastoma cells with GMT phenotype might be more likely to constitute VM, and co-expression of ObR and CD133 or Nestin to constitute the channel impliated that ObR-positive glioblastoma cells displayed glioblastoma stem cells (GSC) properties.
|
28938545 |
2017 |
|
Glioblastoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Because AC133 and 293C antibodies do not detect all CD133 variants in glioblastoma cells, alternate detection methods need to be utilized for complete analysis of CD133 expression and for accurately determining the relationship between CD133 and cancer stem-like cells.
|
20428792 |
2010 |
|
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Bioinformatics data have indicated that dopamine receptor (DRD) 2, DRD4, CD133 and Nestin were elevated in GBM clinical samples and correlated to Temozolomide (TMZ) resistance and increased aldehyde dehydrogenase (ALDH) activity (3.5-8.9%) as well as enhanced (2.1-2.4-fold) neurosphere formation efficiency in U87MG and D54MG GBM cell lines.
|
31561595 |
2019 |
|
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
CD9 silencing in three CD133+ glioblastoma cell lines (NCH644, NCH421k and NCH660h) led to decreased cell proliferation, survival, invasion, and self-renewal ability, and altered expression of the stem-cell markers CD133, nestin and SOX2.
|
26573230 |
2016 |
|
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Co-immunofluorescence staining demonstrated the co-localization of CD133- and LGR5-positive cells in glioblastoma tissue sections.
|
22805276 |
2013 |
|
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Coexpression analysis of CD133 and CD44 identifies proneural and mesenchymal subtypes of glioblastoma multiforme.
|
25749043 |
2015 |
|
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Differential distribution of erbB receptors in human glioblastoma multiforme: expression of erbB3 in CD133-positive putative cancer stem cells.
|
20467331 |
2010 |